Deal­ing Bio­gen an­oth­er blow, EMA rec­om­mends re­ject­ing Aduhelm in three terse para­graphs

The Eu­ro­pean Med­i­cines Agency an­nounced Fri­day it rec­om­mend­ed the Eu­ro­pean Com­mis­sion re­ject Aduhelm, deal­ing a new — al­beit ex­pect­ed — blow to Bio­gen’s hopes of find­ing a wide­spread mar­ket for its strug­gling Alzheimer’s drug.

The EMA rec­om­men­da­tion had been ex­pect­ed for a month, since the EMA’s hu­man med­i­cines com­mit­tee gave Bio­gen “a neg­a­tive trend vote” af­ter an oral pre­sen­ta­tion from the com­pa­ny. As such Bio­gen’s stock, which has lost all the stratos­pher­ic val­ue it gained af­ter Aduhelm’s ap­proval in June, on­ly ticked down 3% pre-mar­ket Fri­day, from $235.52 to $235.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER